New Insights into Mesothelioma Immunotherapy
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Cellular Biochemistry".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 2722
Special Issue Editor
Interests: mesothelioma; immunotherapy; immune checkpoint blockade; EMT gene signature
Special Issue Information
Dear Colleagues,
Mesothelioma is a rare cancer associated with exposure to asbestos. Malignant pleural mesothelioma (MPM) is the most common but the prognosis is quite poor. Conventional therapies have very limited efficacy for this disease. Immunotherapy has shown to be promising in preclinical studies and clinical trials; in particular, novel therapy targeting the immune check points has resulted in significant improvement of clinical outcome of the patients with mesothelioma.
The aim of this Special Issue of Biomolecules is to highlight the most recent progress in mesothelioma immunotherapy, which covers mesothelioma, including malignant pleural mesothelioma (MPM) and peritoneal mesothelioma, immunotherapy, immunology, immune profiling, immune response, immunosuppression, immune checkpoint and its inhibitor, immune score, tumor immune microenvironment, and EMT gene signature, etc. We encourage contributions on the topics above as well as molecular biology, genetics, multi-omics, bioinformatics, and meta-analysis computational studies. Basic study and clinical trials addressing this topic are both of particular interest.
Dr. Licun Wu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mesothelioma/malignant pleural mesothelioma (MPM)/peritoneal mesothelioma
- immunotherapy
- immunology
- immune profiling
- immune response
- immunosuppression
- immune checkpoint/inhibitor
- immune score
- tumor immune microenvironment
- epithelial-mesenchymal transition (EMT) gene signature
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
